BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V

BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT's selective RAS:PI3Kα breaker

Preliminary clinical data from the BBO-11818 Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety, with additional data expected in the second half of 2026; internal combination with BBO-10203 is anticipated to open later in 2026

SOUTH SAN FRANCISCO, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the publication of preclinical data describing the discovery and characterization of BBO-11818, a panKRAS inhibitor targeting KRAS in both the ON and OFF states, with significant therapeutic potential for patients with KRAS mutant cancers. The publication, titled "Discovery of BBO-11818, a Potent and Selective Non-covalent Inhibitor of (ON) and (OFF) KRAS with Activity Against Multiple Oncogenic Mutants" was published in the peer-reviewed journal Cancer Discovery, a journal of the American Association for Cancer Research's (AACR).